Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

Comprehensive SWOT analysis reveals Gilead Sciences Inc's strategic positioning in the pharmaceutical industry. Financial ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

US biotech major Gilead Sciences was trading nearly 2% higher in pre-market on Thursday after announcing its third-quarter ...

In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Regeneron Pharmaceuticals and Amgen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance. Gilead ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.